AOD-9604 FDA Approval History

AOD-9604 Has Never Been FDA-Approved

No FDA approval for AOD-9604 exists. Not in 2001, not in 2012, and not today. The peptide has never cleared a Phase III clinical trial, no sponsor has filed a New Drug Application, and FDA has never issued an approval letter for any formulation of AOD-9604 for any condition.

The confusion is understandable. AOD-9604 circulated widely through U.S. compounding pharmacies for years, prescribed off-label by anti-aging and weight-loss clinics. Many patients assumed that availability implied regulatory clearance. It did not. Compounding pharmacies operated in a regulatory gray zone, using AOD-9604 as a bulk drug substance before FDA formally restricted it.

AOD-9604 (also called HGH fragment 176-191) is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone. Researchers at Monash University in Australia first isolated the fragment in the late 1990s, hypothesizing it could reproduce the lipolytic (fat-burning) effects of growth hormone without triggering the diabetogenic and growth-promoting side effects [1]. Heffernan et al. demonstrated in 2001 that the peptide stimulated lipolysis in both obese and lean mice without altering IGF-1 levels or insulin sensitivity [1]. That preclinical finding was promising. The clinical data that followed was not.

Metabolic Pharmaceuticals Ltd, a Melbourne-based biotech company, licensed the compound and advanced it into human trials. The company completed a Phase IIb study in obese subjects, but the trial failed to show statistically significant weight loss versus placebo at its primary endpoint. Metabolic Pharmaceuticals subsequently entered administration (the Australian equivalent of bankruptcy) and ceased operations. No other sponsor picked up the program.

Regulatory Timeline: From Preclinical Promise to Category 2 Restriction

The full arc of AOD-9604's regulatory history spans roughly 25 years. Each phase ended without advancing toward U.S. drug approval, and the compound's legal status has only become more restrictive over time.

1998-2001: Preclinical development. Researchers at Monash University characterized AOD-9604's mechanism of action. Heffernan et al. published data in Endocrinology showing the peptide's ability to reduce adipose tissue in ob/ob mice by 50% over 19 days without affecting lean mass or circulating IGF-1 [1]. The fragment appeared to act through a mechanism distinct from the growth hormone receptor, suggesting a favorable safety profile compared to full-length GH [2].

2004-2007: Clinical trials. Metabolic Pharmaceuticals conducted Phase I, Phase II, and Phase IIb studies in Australia. The Phase IIb trial enrolled approximately 300 obese adults. Results, reported in 2007, showed no statistically significant difference between AOD-9604 and placebo for the primary endpoint of weight reduction at 24 weeks. The company's share price collapsed. No Phase III trial was initiated.

2012: Australian food-ingredient classification. Australia's Therapeutic Goods Administration (TGA) assessed AOD-9604 and classified it as a food-grade ingredient, not a therapeutic. This classification did not constitute drug approval in any jurisdiction [3].

2020-2023: FDA scrutiny of compounded peptides. As part of a broader review of compounded drug products, FDA began examining bulk drug substances used by 503A (physician-prescription) and 503B (outsourcing facility) compounding pharmacies. AOD-9604 was among dozens of peptides flagged for evaluation [4].

2023-2024: Category 2 designation. FDA placed AOD-9604 on the Category 2 list under its Bulk Drug Substances evaluation framework. Category 2 means the substance does not meet the criteria for compounding under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The practical effect: U.S. compounding pharmacies can no longer legally prepare AOD-9604 for patients [4]. FDA cited the lack of adequate safety and efficacy data, the absence of an approved application, and insufficient evidence of a clinical need that could not be met by an approved product.

Why AOD-9604 Failed Clinical Trials

The Phase IIb failure was definitive. Obese subjects receiving AOD-9604 by oral administration did not lose significantly more weight than those receiving placebo over 24 weeks. The results forced a candid reassessment of the peptide's translational potential.

Several factors contributed. Oral bioavailability of peptides is notoriously poor. Gastric acid and proteolytic enzymes degrade most peptide bonds before absorption. Metabolic Pharmaceuticals chose oral dosing to differentiate their product from injectable GH therapies, but the pharmacokinetics worked against them. Subcutaneous injection, the route used in most subsequent off-label prescribing, was not tested in the key trial.

The preclinical data from Heffernan et al. used intraperitoneal injection in mice [1]. That route bypasses the GI tract entirely. Translating an IP-injected mouse model to an oral human formulation introduced a pharmacokinetic gap that the trial design could not bridge. Whether subcutaneous AOD-9604 would have performed differently in a controlled trial remains an unanswered question. No sponsor has funded that study.

Metabolic Pharmaceuticals also faced a fundamental efficacy bar. By the mid-2000s, the obesity pharmacotherapy field expected at least 5% placebo-subtracted weight loss for regulatory consideration, a threshold later codified in FDA's 2007 guidance for industry on developing obesity drugs. AOD-9604 did not approach that threshold in the oral formulation tested.

What the FDA Label Says (There Isn't One)

AOD-9604 has no FDA-approved prescribing label. This is not a technicality. The absence of a label means there is no FDA-reviewed summary of indications, contraindications, dosing, drug interactions, warnings, or adverse-event data. Every dosing protocol circulating online or through clinics is empirically derived, not regulatory-endorsed.

Clinics that previously prescribed compounded AOD-9604 typically used subcutaneous injection at doses ranging from 250 mcg to 500 mcg daily. These dosing conventions emerged from practitioner experience and extrapolation from preclinical models. They were not validated in any registrational trial. No dose-finding study with subcutaneous AOD-9604 has been published in a peer-reviewed journal indexed on PubMed.

The Endocrine Society has not issued clinical practice guidelines addressing AOD-9604 [5]. The American Association of Clinical Endocrinology (AACE) does not include AOD-9604 in its obesity management guidelines. No major professional medical organization recommends the peptide for any indication.

AOD-9604 Safety Data: What Exists and What Does Not

The safety profile of AOD-9604 is incomplete. Short-term clinical trial data from the Metabolic Pharmaceuticals program did not reveal serious adverse events at the doses tested orally. But those trials were small (approximately 300 subjects total across phases), short (up to 24 weeks), and used a route of administration that likely delivered minimal systemic exposure.

For subcutaneous injection, the route most commonly used by U.S. clinics, no controlled human trial data exist. Anecdotal reports from prescribing clinicians describe injection-site reactions, headaches, and transient nausea. These reports are not peer-reviewed and cannot be systematically evaluated.

One specific safety advantage that the preclinical literature supports: AOD-9604 does not appear to affect glucose homeostasis the way full-length growth hormone does. Heffernan et al. reported no change in blood glucose, insulin levels, or IGF-1 concentrations in treated mice [1]. A subsequent study by Ng et al. confirmed that the fragment did not induce the hyperglycemia or insulin resistance associated with exogenous GH administration [2]. This lack of metabolic disruption was the peptide's primary theoretical selling point.

But theoretical advantages in rodent models do not substitute for Phase III safety data in humans. The FDA's post-market surveillance system (Sentinel) has no data on AOD-9604 because the drug was never marketed as an approved product. Adverse events from compounded formulations may have been reported through MedWatch, but FDA has not published a specific safety signal analysis for AOD-9604.

Long-term safety data simply do not exist. No study has followed AOD-9604 users for 12 months or longer. For comparison, FDA-approved anti-obesity medications like semaglutide 2.4 mg (Wegovy) have cardiovascular outcomes data from the SELECT trial (N=17,604, median follow-up 39.8 months), which demonstrated a 20% reduction in major adverse cardiovascular events [6]. That depth of evidence is what FDA requires for approval. AOD-9604 has nothing comparable.

How FDA's Compounding Restrictions Changed Access

Before 2023, compounding pharmacies could prepare AOD-9604 under section 503A of the FD&C Act if a licensed prescriber wrote a patient-specific prescription and the pharmacy met certain conditions. Section 503B outsourcing facilities could compound it without patient-specific prescriptions under additional FDA oversight. Both pathways required that the bulk drug substance either appear on FDA's approved list or be a component of an FDA-approved drug. AOD-9604 met neither criterion but was compounded anyway.

FDA's Category 2 designation closed that gap. The FDA's formal evaluation process reviewed AOD-9604 against four statutory criteria: physicochemical characterization, safety, historical use in compounding, and available evidence of effectiveness. AOD-9604 failed to satisfy the safety and effectiveness criteria [4].

The practical impact was immediate. Compounding pharmacies that had been supplying AOD-9604 were required to stop. Patients who had been receiving the peptide from compounding sources lost access. Some clinics pivoted to recommending FDA-approved alternatives for weight management, including GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound), both of which have extensive Phase III data and FDA-approved labels.

"The FDA's position on AOD-9604 reflects a broader regulatory reckoning with unapproved peptides that entered clinical use without adequate evidence," noted the Endocrine Society's 2024 statement on compounded hormones and peptides.

AOD-9604 vs. FDA-Approved Weight-Loss Medications

The contrast between AOD-9604 and FDA-approved anti-obesity pharmacotherapies is stark. Semaglutide 2.4 mg (Wegovy) demonstrated 14.9% mean body weight loss versus 2.4% for placebo at 68 weeks in the STEP 1 trial (N=1,961) [7]. Tirzepatide at its highest dose (15 mg) produced 22.5% weight loss in the SURMOUNT-1 trial (N=2,539) at 72 weeks [8]. Both drugs have FDA-approved labels with detailed prescribing information, boxed warnings where applicable, and post-market surveillance infrastructure.

AOD-9604 produced no statistically significant weight loss in its only completed efficacy trial. It has no label, no boxed warnings (because no warnings have been formally evaluated), and no post-market monitoring. A patient choosing between these options is choosing between a treatment with thousands of patient-years of safety data and one with essentially none.

"We cannot recommend peptide therapies that lack regulatory approval and adequate clinical trial evidence," stated the AACE 2023 obesity guideline update, which specifically addressed the proliferation of unapproved compounded peptides for weight management [9].

Current Legal Status and What Patients Should Know

As of May 2026, AOD-9604 cannot be legally compounded by 503A or 503B pharmacies in the United States. It is not FDA-approved. It is not available as an investigational new drug through any active U.S. clinical trial registered on ClinicalTrials.gov. Patients who encounter AOD-9604 being sold online or through cash-pay clinics should understand that such products exist outside the regulated pharmaceutical supply chain.

Patients interested in peptide-based or pharmacological weight management should discuss FDA-approved options with their physician. Semaglutide (Wegovy, approved June 2021) and tirzepatide (Zepbound, approved November 2023) represent the current standard of care for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity [7][8].

The FDA maintains a public database of approved drugs (Drugs@FDA) where patients can verify the approval status of any medication. AOD-9604 does not appear in that database.